A pooled analysis of mortality in patients with COPD receiving dual bronchodilation with and without additional inhaled corticosteroid

M Miravitlles, K Verhamme, PMA Calverley… - … journal of chronic …, 2022 - Taylor & Francis
Background Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) …
被引用次数：17 相关文章
[HTML] nih.gov

[HTML][HTML] A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid

M Miravitlles, K Verhamme, PMA Calverley… - … Journal of Chronic …, 2022 - ncbi.nlm.nih.gov
Background Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA)/inhaled corticosteroid (ICS) …

A pooled analysis of mortality in patients with COPD receiving dual bronchodilation with and without additional inhaled corticosteroid

M Miravitlles, K Verhamme, P Calverley… - … journal of chronic …, 2022 - aura.abdn.ac.uk
Background: Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/longacting β2-agonist (LABA)/inhaled corticosteroid (ICS) …
[PDF] eur.nl

[PDF][PDF] A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid

M Miravitlles, K Verhamme, PMA Calverley… - International Journal of …, 2022 - pure.eur.nl
Background: Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/longacting β2-agonist (LABA)/inhaled corticosteroid (ICS) …
[PDF] scienceopen.com

[PDF][PDF] A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid

M Miravitlles, K Verhamme… - … Journal of Chronic …, 2022 - scienceopen.com
Background: Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/longacting β2-agonist (LABA)/inhaled corticosteroid (ICS) …

A pooled analysis of mortality in patients with COPD receiving dual bronchodilation with and without additional inhaled corticosteroid

M Miravitlles, KMC Verhamme… - … journal of chronic …, 2022 - abdn.elsevierpure.com
Background: Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/long-acting β2-agonist LABA)/inhaled corticosteroid (ICS) …

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.

M Miravitlles, K Verhamme, PMA Calverley… - … Journal of Chronic …, 2022 - europepmc.org
Background Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA)/inhaled corticosteroid (ICS) …
[PDF] academia.edu

[PDF][PDF] A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid

M Miravitlles, K Verhamme, PMA Calverley… - International Journal of …, 2022 - academia.edu
Background: Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/longacting β2-agonist (LABA)/inhaled corticosteroid (ICS) …

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid

M Miravitlles, K Verhamme, PMA Calverley… - … Journal of Chronic …, 2022 - dovepress.com
Background: Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA)/inhaled corticosteroid (ICS) …

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid

M Miravitlles, K Verhamme… - … journal of chronic …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA)/inhaled corticosteroid (ICS) …